NuGenerex
IMMUNO-ONCOLOGY
AE37 immunotherapeutic vaccine for Breast, Prostate, Bladder
NuGenerex
HEALTH
Ancillary health management services for chronic conditions
NuGenerex
REGENERATIVE
Olaregen Therapeutix, Regentys
NuGenerex
DIAGNOSTICS
NGDx Express II rapid diagnostic tests for infectious disease
NuGenerex
THERAPEUTICS
Oral-lyn (Buccal Insulin) and RapidMist Buccal delivery technology
WELCOME TO GENEREX BIOTECHNOLOGY
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.
End-to-End Solutions for patient centric care from rapid diagnosis through delivery of personalized therapies
RECENT NEWS
Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA
MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be...
NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
Ii-Key Immunotherapeutic Vaccine Technology Ii-Key-SARS-CoV-2 Vaccine Market Potential & International Contracts Market Potential for AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine for breast, prostate, and bladder cancers MIRAMAR, Fla., June 22, 2021 (GLOBE...